Amphastar Pharmaceuticals Income After Taxes 2012-2024 | AMPH

Amphastar Pharmaceuticals income after taxes from 2012 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Amphastar Pharmaceuticals Annual Income After Taxes
(Millions of US $)
2023 $140
2022 $93
2021 $64
2020 $1
2019 $47
2018 $-7
2017 $4
2016 $10
2015 $-3
2014 $-11
2013 $12
2012 $18
2011 $8
2009 $23
Amphastar Pharmaceuticals Quarterly Income After Taxes
(Millions of US $)
2024-06-30 $38
2024-03-31 $44
2023-12-31 $37
2023-09-30 $50
2023-06-30 $26
2023-03-31 $27
2022-12-31 $34
2022-09-30 $16
2022-06-30 $18
2022-03-31 $25
2021-12-31 $20
2021-09-30 $31
2021-06-30 $9
2021-03-31 $4
2020-12-31 $-6
2020-09-30 $5
2020-06-30 $-1
2020-03-31 $4
2019-12-31 $1
2019-09-30 $1
2019-06-30 $47
2019-03-31 $-2
2018-12-31 $2
2018-09-30 $2
2018-06-30 $-3
2018-03-31 $-7
2017-12-31 $1
2017-09-30 $0
2017-06-30 $2
2017-03-31 $1
2016-12-31 $-3
2016-09-30 $4
2016-06-30 $7
2016-03-31 $2
2015-12-31 $8
2015-09-30 $-3
2015-06-30 $-7
2015-03-31 $-1
2014-12-31 $-3
2014-09-30 $-5
2014-06-30 $-1
2014-03-31 $-2
2013-12-31 $2
2013-09-30 $-0
2013-06-30 $8
2013-03-31 $2
2012-12-31 $52
2012-09-30 $57
2012-06-30 $49
2012-03-31 $46
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.438B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.120B 6.83
Dr Reddy's Laboratories (RDY) India $13.079B 19.59
BridgeBio Pharma (BBIO) United States $5.045B 0.00
Bausch Health Cos (BHC) Canada $2.956B 2.23
Supernus Pharmaceuticals (SUPN) United States $1.771B 357.00
Taysha Gene Therapies (TSHA) United States $0.449B 73.00
Personalis (PSNL) United States $0.315B 0.00
Assembly Biosciences (ASMB) United States $0.117B 0.00
Acasti Pharma (ACST) Canada $0.028B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00